DavidPRyanMD

Oncology • Boston, MA

Gastrointestinal Cancer, Hematologic Oncology

Chief, Hematology-Oncology, Clinical Director, MGH Cancer Center

Join to view full profile

Dr. Ryan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ryan's full profile

Already have an account?

Office
55 Fruit St
Yaw 7e
Boston, MA 02114
Phone+1 617-724-0245

Fax+1 617-724-3166

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 1999
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1992 - 1996
Columbia University Vagelos College of Physicians and SurgeonsClass of 1992

Certifications & Licensure

MA State Medical License 1996 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2014
Boston Magazine Castle Connolly, 2010-2013
America's Top Doctors for Cancer Castle Connolly, 2010-2013

Clinical Trials

Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum Start of enrollment: 2000 Jul 01
Completed
Phase 1, Phase 2
Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer Start of enrollment: 2004 Jul 01
Unknown status
Phase 3
Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer Start of enrollment: 2005 Jul 01
Completed
Phase 2
Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer Start of enrollment: 2008 May 01
Terminated
Phase 2
Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma Start of enrollment: 2008 Apr 01
Terminated
Phase 1, Phase 2
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Start of enrollment: 2012 Jul 01
Completed
Phase 2
Study of Vitamin D in Untreated Metastatic Colorectal Cancer Start of enrollment: 2012 Apr 13
Completed
Phase 2
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer Start of enrollment: 2014 Sep 01
Terminated
Phase 2
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors Start of enrollment: 2016 Jun 14
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Hypofractionated Radiotherapy-Related Lymphopenia Is Associated With Worse Survival in Unresectable Intrahepatic Cholangiocarcinoma.
Grace Lee, Daniel W Kim, Alicia C Smart, Nora K Horick, Christine E Eyler
American Journal of Clinical Oncology. 2024-08-01
1 citations
Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Ductal Ade...
Samantha Guinn, Benedict Kinny-Köster, Joseph A Tandurella, Jacob T Mitchell, Dimitrios N Sidiropoulos
Cancer Research. 2024-05-02
Chief's Perspective on Physician Burnout.
David P Ryan
JCO Oncology Practice. 2024-01-01

Lectures

Optimizing Locoregional Management in the Context of Multidisciplinary Care
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020

Other

Clinical features, staging, and treatment of anal cancer
Ryan DP, Willett CG
http://www.uptodate.com/contents/clinical-features-staging-and-treatment-of-anal-cancer
UpToDate, Wolters Kluwer Health - 2013-03-26
Ampullary carcinoma: Treatment and prognosis
Ryan DP, Castillo CF, Mamon H
http://www.uptodate.com/contents/ampullary-carcinoma-treatment-and-prognosis
UpToDate, Wolters Kluwer Health - 2012-07-19
Classification and epidemiology of anal cancer
Ryan DP, Willett CG
http://www.uptodate.com/contents/classification-and-epidemiology-of-anal-cancer
UpToDate, Wolters Kluwer Health - 2012-12-20
Adjuvant therapy for resected rectal cancer
Ryan DP, Willett CG
http://www.uptodate.com/contents/adjuvant-therapy-for-resected-rectal-cancer
UpToDate, Wolters Kluwer Health - 2013-04-09
Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer
Ryan DP, Willett CG
http://www.uptodate.com/contents/neoadjuvant-chemoradiotherapy-and-radiotherapy-for-rectal-cancer
UpToDate, Wolters Kluwer Health - 2013-03-18
Treatment of locally advanced unresectable or recurrent rectal cancer
Ryan DP, Willett CG, Rodriguez-Bigas MA
http://www.uptodate.com/contents/treatment-of-locally-advanced-unresectable-or-recurrent-rectal-canc
UpToDate, Wolters Kluwer Health - 2013-03-28
Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer
Ryan DP, Mamon H
http://www.uptodate.com/contents/adjuvant-and-neoadjuvant-therapy-for-exocrine-pancreatic-cancer
UpToDate, Wolters Kluwer Health - 2013-02-19
Chemotherapy for advanced exocrine pancreatic cancer
Ryan DP
http://www.uptodate.com/contents/chemotherapy-for-advanced-exocrine-pancreatic-cancer
UpToDate, Wolters Kluwer Health - 2013-04-01
Management of locally advanced and borderline resectable exocrine pancreatic cancer
Ryan DP, Mamon H
http://www.uptodate.com/contents/management-of-locally-advanced-and-borderline-resectable-exocrine-p
UpToDate, Wolters Kluwer Health - 2013-04-10
Join now to see all

Press Mentions

After Dana-Farber Split, Mass General Brigham Cuts New Cancer PathDecember 3rd, 2024
Dana-Farber, Brigham Split Creates New Opportunities for Cancer CareNovember 1st, 2024
$1 Million Gift to Mass General Cancer Center Will Support Promising Research Conducted by Pioneering Physician-ScientistsOctober 21st, 2024
Join now to see all